Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Grants Orphan Drug Designation to LP-284 for High-Grade B-Cell Lymphomas

December 4th 2023

The FDA has granted orphan drug designation to LP-284 for use in the treatment of patients with high-grade B-cell lymphoma harboring MYC and BCL2 rearrangements.

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 30th 2023

Drs Lunning and Jacobson discuss the characteristics of follicular lymphoma that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.

Dr Phillips on the Shifting Treatment Paradigm For CAR T-Cell Therapy in LBCL

November 28th 2023

Adrienne Phillips, MD, MPH, discusses the impact of CAR T-cell therapy on the treatment paradigm for patients with large B-cell lymphoma, highlighting key advancements in the decision-making process for CAR T-cell therapy selection.

Hematologists Dive into the Current Treatment Landscape

November 28th 2023

Ehab L. Atallah, MD, highlights updates in chronic lymphocytic leukemia, emphasizing the importance of understanding the plethora of options that are present for oncologists treating patients within this population.

CAR T-Cell Therapy’s Impact on Lymphoma Management

November 28th 2023

Gain insights into CAR T-cell therapy's impact on lymphoma treatment through a historical perspective and mechanism of action.

Advancing Lymphoma Treatments: CAR T-Cell and Bispecific Therapies

November 28th 2023

Discover cutting-edge cellular therapeutics, CAR T-cell therapy, and bispecific strategies for treating lymphoma patients in clinical trials.

FDA Approval Sought for Obe-Cel in Relapsed/Refractory B-ALL

November 27th 2023

A biologics license application seeking the approval of obecabtagene autoleucel for the treatment of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia has been submitted to the FDA.

Large B-Cell Lymphoma: Treatment Approaches and Evolving Therapies

November 22nd 2023

Expert insight into current treatment strategies and emerging therapies for diffuse large B-cell lymphoma, a challenging malignancy.

Understanding LBCL: Presentation, Diagnosis, and Prognostic Indicators

November 22nd 2023

Explore the diverse ways large B-cell lymphoma can manifest, the diagnostic process, and prognostic indicators for effective management.

Dr Phillips on the Management of Toxicities Associated With CAR T-Cell Therapy

November 21st 2023

Adrienne Phillips, MD, MPH, discusses the management of toxicities associated with CAR T-cell therapy across hematologic malignancies.

Regulatory Decisions and Research Boost Management Strategies for Hematologic Malignancies

November 15th 2023

Andrew Kuykendall, MD, discusses the current role of JAK inhibitors in myelofibrosis, the importance of chronic graft-vs-host disease awareness in patients with myeloid malignancies receiving transplant, and unmet needs for patients with chronic myelomonocytic leukemia.

Bayer Withdraws US Indication for Copanlisib in Relapsed Follicular Lymphoma

November 13th 2023

Bayer has announced the intention to voluntarily withdraw the new drug application for copanlisib in adult patients with relapsed follicular lymphoma who have previously received at least 2 prior systemic treatments.

FDA Places Partial Clinical Hold on Phase 1 Trial of NX-2127 in R/R B-Cell Malignancies

November 2nd 2023

The FDA has placed a partial clinical hold on the phase 1 NX-2127-001 trial investigating the novel BTK degrader NX-2127 in patients with relapsed/refractory B-cell malignancies.

Social Determinants of Health Impact Survival Outcomes in Patients With Hematologic Malignancies

October 29th 2023

Marisol Miranda-Galvis, DDS, MS, PhD, highlights the importance of understanding which social determinants of health have the greatest influence on treatment-related outcomes in patients with hematologic malignancies, expands on key variables identified in a systematic review of these disparities, and emphasizes the importance of continuing to implement new strategies to increase access to quality treatments.

Further Research Is Needed to Maximize Efficacy of Current Treatment Options in Hematologic Malignancies

October 26th 2023

Ricardo D. Parrondo, MD, highlights the current use of covalent BTK inhibitors in chronic lymphocytic leukemia, potential roles for the non-covalent BTK inhibitor pirtobrutinib, and the importance of future research on time-limited treatment options for patients with newly diagnosed chronic lymphocytic leukemia.

Brentuximab Vedotin Plus AVD Wins EU Approval for Previously Untreated CD30+ Stage III Hodgkin Lymphoma

October 19th 2023

The European Commission has approved brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult patients with previously untreated, CD30-positive, stage III Hodgkin lymphoma.

Unmet Needs and Future of Lower-Risk MDS

October 19th 2023

The panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.

SLS009 Plus Venetoclax/Azacitidine Displays Activity, Tolerability in Relapsed/Refractory AML

October 17th 2023

The addition of SLS009 to the combination of venetoclax and azacitidine produced anti-leukemic effects and was safe in patients with relapsed/refractory acute myeloid leukemia who did not respond or stopped responding to venetoclax-based therapies.

FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia

October 16th 2023

Dr Kuykendall discusses the FDA approval of momelotinib in myelofibrosis with anemia, key data from the MOMENTUM trial, and how momelotinib alters the myelofibrosis treatment paradigm.

Treatment Strategies and Sequencing in MDS

October 12th 2023

Rami Komrokji, MD, provides clinical insights on treatment decision-making, sequencing, and combinations for patients with myelodysplastic syndrome. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.